SLN

Flash News: OKX Lists Smart Layer's SLN Token on its Spot Market

Retrieved on: 
Friday, February 23, 2024

OKX today announced that it has listed Smart Layer 's SLN token on its spot market on February 23 at 8:00 AM (UTC).

Key Points: 
  • OKX today announced that it has listed Smart Layer 's SLN token on its spot market on February 23 at 8:00 AM (UTC).
  • Smart Layer is a token-incentivised network of service nodes that drives its operations and incentivizes nodes to contribute their resources.
  • It consists of three key components: the blockchain, Anchoring Nodes and Service Nodes.
  • The network creates a secure and efficient environment, with both Anchoring and Service nodes being rewarded with Smart Layer tokens for their participation.

Flash News: OKX to Add Smart Layer's SLN Token to its Spot Market

Retrieved on: 
Wednesday, February 21, 2024

OKX today announced that it will list Smart Layer 's SLN token on its spot market on February 23 at 8:00 AM (UTC).

Key Points: 
  • OKX today announced that it will list Smart Layer 's SLN token on its spot market on February 23 at 8:00 AM (UTC).
  • Smart Layer is a token-incentivised network of service nodes that drives its operations and incentivizes nodes to contribute their resources.
  • It consists of three key components: the blockchain, Anchoring Nodes and Service Nodes.
  • The network creates a secure and efficient environment, with both Anchoring and Service nodes being rewarded with Smart Layer tokens for their participation.

New Indication Approved for Verdye (Indocyanine Green for Injection, ICG) for Breast Sentinel Lymph Node Mapping

Retrieved on: 
Monday, February 5, 2024

ATHLONE, Ireland, Feb. 5, 2024 /PRNewswire/ -- Diagnostic Green Plc (Diagnostic Green) is pleased to announce the approval of Verdye (ICG) for intraoperative identification of sentinel lymph nodes and visualisation pathways in breast cancer in Spain.

Key Points: 
  • ATHLONE, Ireland, Feb. 5, 2024 /PRNewswire/ -- Diagnostic Green Plc (Diagnostic Green) is pleased to announce the approval of Verdye (ICG) for intraoperative identification of sentinel lymph nodes and visualisation pathways in breast cancer in Spain.
  • The presence of lymphatic metastases is an important prognostic factor for the survival of breast cancer.
  • Sentinel lymph node biopsy (SLNB) continues to be a fundamental component of early breast cancer detection and is the current standard of care to help determine whether cancer has spread to the lymph nodes.
  • Verdye (Indocyanine Green, ICG) is available throughout EMEA and sold through a network of distributors or directly by Diagnostic Green.

INVO Bioscience Files S-4 Registration and Preliminary Joint Proxy Statements in Connection with Merger with NAYA Biosciences, NAYA Announces New Board Directors

Retrieved on: 
Wednesday, January 17, 2024

NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024.

Key Points: 
  • NAYA has also announced that five new board directors have joined its leadership team effective January 1st, 2024.
  • “NAYA is thrilled to welcome new board members with outstanding executive and entrepreneurial track records,” commented NAYA CEO Dr. Daniel Teper.
  • She is currently Executive Engagement Lead at Publicis, the 2nd largest communications group in the world, where she launched multiple brands as Chief Marketing Officer.
  • He previously held several leadership positions in corporate and business development and partnerships at Sanofi.

Castle Biosciences Announces Multiple Data Presentations at the 2023 American Society for Dermatologic Surgery Annual Meeting

Retrieved on: 
Tuesday, November 14, 2023

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced that data spanning its dermatologic portfolio of gene expression profile (GEP) tests was recently presented at the 2023 American Society for Dermatologic Surgery (ASDS) Annual Meeting in Chicago.
  • “The robust data presented at ASDS underscores the value of GEP testing across multiple skin cancer indications” said Robert Cook, Ph.D., senior vice president of research and development at Castle Biosciences.
  • Summary: ART is recommended based on high-risk clinicopathologic features of SCC, but these criteria are wide-ranging, encompassing a broad range of patients.
  • Additionally, a DecisionDx-SCC Class 2B result was the only risk factor that successfully identified patients who would benefit from ART.

Arizona Approves SaniDate® 12.0 for Human Health Pathogen Control in Agricultural Irrigation Waters!

Retrieved on: 
Thursday, November 30, 2023

EAST HARTFORD, Conn., Nov. 30, 2023 /PRNewswire/ -- Just in time for fall/winter vegetable season, BioSafe Systems' product SaniDate® 12.0 received a FIFRA 24(c) Special Local Need (SLN) label in Arizona to control foodborne human health pathogens in agricultural irrigation water.

Key Points: 
  • EAST HARTFORD, Conn., Nov. 30, 2023 /PRNewswire/ -- Just in time for fall/winter vegetable season, BioSafe Systems' product SaniDate® 12.0 received a FIFRA 24(c) Special Local Need (SLN) label in Arizona to control foodborne human health pathogens in agricultural irrigation water.
  • Specifically, SaniDate 12.0 is the only labeled product that can be used for the reduction and control of Shiga Toxin-producing Escherichia coli (STEC), including O157:H7 and Salmonella enterica in preharvest agriculture water.
  • SaniDate 12.0 is one of the first products to receive this 24(c) SLN, reinforcing BioSafe Systems' dedication to strengthening food safety not only in the state of Arizona but throughout the country.
  • A special local need label may also be produced if the product is more effective or less harmful than the one currently in use.

DecisionDx®-Melanoma Outperforms Memorial Sloan Kettering Cancer Center (MSKCC) Nomogram in Predicting Sentinel Lymph Node Positivity in Patients with Cutaneous Melanoma

Retrieved on: 
Thursday, October 5, 2023

Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).

Key Points: 
  • Castle Biosciences, Inc. (Nasdaq: CSTL), a company improving health through innovative tests that guide patient care, today announced a new study demonstrating DecisionDx®-Melanoma outperforms a nomogram developed at the Memorial Sloan Kettering Cancer Center (MSKCC) in predicting the risk of sentinel lymph node (SLN) positivity in patients with cutaneous melanoma (CM).
  • The MSKCC nomogram, which uses logistic regression and only clinical and pathologic factors to predict a patient’s SLN positivity risk.
  • Patients from previously published multicenter cohorts with T1-T2 tumors who had undergone the SLNB procedure (n=465) were analyzed using both DecisionDx-Melanoma and the MSKCC nomogram.
  • DecisionDx-Melanoma also demonstrated better accuracy in predicting SLN positivity, including higher sensitivity (95% vs. 81%) and negative predictive value (97% vs. 90%) than the MSKCC nomogram.

Groupize Launches HCP Digital Sign-In Solution, Expanding its Total Meetings Management Platform

Retrieved on: 
Wednesday, May 3, 2023

BOSTON, May 3, 2023 /PRNewswire-PRWeb/ -- Groupize, the Total Meeting Management platform, today launched 'HCP Digital Sign-In,' its newest module designed to complement their Speaker Bureau Travel and Meetings Management solutions for the Life Sciences industry. With this expansion, Pharmaceutical and Medical Device field representatives can seamlessly maintain compliance with US Federal Open Payments (Sunshine Act) while engaging with Healthcare Professionals (HCPs). This includes a wide range of event types, such as office visits, speaker bureaus, dinner meetings and clinical trials.

Key Points: 
  • This includes a wide range of event types, such as office visits, speaker bureaus, dinner meetings and clinical trials.
  • Coupled with its SAP Concur Expense import feature, HCP Digital Sign-In streamlines the expense management process and reduces errors and time-consuming manual tasks.
  • "We see this as a valuable addition to our comprehensive event platform," said Charles de Gaspe Beaubien, CCO at Groupize.
  • "The HCP Digital Sign-In is the perfect complement to the comprehensive Groupize Event Platform," said Ron Strauss, Vice President Compliance at MiMedx.

Recommendations by Expert Consensus Panel Relating to Risk-Stratification Tests and Tools for Use in Cutaneous Melanoma Have Been Adopted as an Official Policy Recommendation of the National Society for Cutaneous Medicine

Retrieved on: 
Wednesday, March 8, 2023

The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.

Key Points: 
  • The report provides usage guidelines and a framework for clinicians to integrate GEP testing into their CM patient management.
  • Additionally, the consensus report endorses Castle’s DecisionDx®-Melanoma GEP risk stratification test as offering more utility than other existing CM GEP assays or nomograms, supported by extensive, evidence-driven data in current literature.
  • The panel reviewed 32 studies published between 2019 through 2022 assessing the use of GEP testing in CM prognosis.
  • Each of the recommendations was given a strength “A,” “B,” or “C” according to Strength of Recommendation Taxonomy (SORT) criteria.

Data Presentation at 2023 Winter Clinical - Miami™ Highlights Use of DecisionDx®-Melanoma to Guide SLNB Surgery Decisions in Head and Neck Tumors

Retrieved on: 
Wednesday, February 22, 2023

The poster presentation for DecisionDx®-Melanoma strengthens the evidence supporting use of the test to provide risk stratification for patients in order to guide risk-appropriate sentinel lymph node biopsy (SLNB) surgery decisions.

Key Points: 
  • The poster presentation for DecisionDx®-Melanoma strengthens the evidence supporting use of the test to provide risk stratification for patients in order to guide risk-appropriate sentinel lymph node biopsy (SLNB) surgery decisions.
  • This study involved patients with cutaneous melanoma (CM) tumors (T1-T2a) located in the head or neck region who had undergone SLNB (n=159).
  • CM tumors on the head or neck tend to be more aggressive and pose unique challenges for SLNB surgery.
  • Early development data for Castle’s pipeline test for inflammatory skin diseases is expected in 2023, with an expected launch by the end of 2025.